1KA Stock Overview
Together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GH Research PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.80 |
| 52 Week High | US$13.50 |
| 52 Week Low | US$4.70 |
| Beta | 0.79 |
| 11 Month Change | -19.44% |
| 3 Month Change | -46.30% |
| 1 Year Change | -31.36% |
| 33 Year Change | -63.29% |
| 5 Year Change | n/a |
| Change since IPO | -59.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1KA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.7% | -3.0% | -1.9% |
| 1Y | -31.4% | -13.2% | 12.3% |
Return vs Industry: 1KA underperformed the German Pharmaceuticals industry which returned -13.2% over the past year.
Return vs Market: 1KA underperformed the German Market which returned 12.3% over the past year.
Price Volatility
| 1KA volatility | |
|---|---|
| 1KA Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1KA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1KA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 49 | Villy Valcheva | www.ghres.com |
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.
GH Research PLC Fundamentals Summary
| 1KA fundamental statistics | |
|---|---|
| Market cap | €307.64m |
| Earnings (TTM) | -€31.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.7x
P/E RatioIs 1KA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1KA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$34.97m |
| Earnings | -US$34.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1KA perform over the long term?
See historical performance and comparison